Does pulmonary artery denervation improve exercise capacity, hemodynamic status, and clinical outcomes in patients with WHO group 1 PAH?
Pulmonary artery denervation appears to improve exercise capacity, hemodynamics, and clinical outcomes at 6 months in patients with WHO group 1 PAH.
In patients with WHO group 1 PAH, PADN improved exercise capacity, hemodynamic status, and clinical outcomes during 6-month follow-up. (Safety and Efficacy of Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension PADN-CFDA; NCT03282266).
Zhang et al. (Sun,) studied this question.